What amount sold does Alveus Therapeutics, Inc. report in Form D filings?

The latest linked filings report $56.9M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Alveus Therapeutics, Inc.'s most recent SEC filing?

Alveus Therapeutics, Inc.'s most recent Form D filing was on 2025-12-29.

How many investors does Alveus Therapeutics, Inc. have?

The most recent Form D filing lists 17 investor(s).

Alveus Therapeutics, Inc.

CIK: 0002075856·Pharmaceuticals·PHILADELPHIA, PA

Reported Sold

$56,862,480

Total Filings

Identified Offerings

Last Filed

Dec 29, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

Offering filing timeline

Dec 29, 2025Form D — New notice

Reported sold: $56,862,480 · Target: $110,724,980

Rule 506(b)·17 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

N/A

Amendment Rate

Latest reported sold across 1 identified offering

$56,862,480

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Gregory Parekh

Director

Appears on 1 filing

Ivan Gergel

Director

Appears on 1 filing

Garrett Ingram

Director

Appears on 1 filing

Carlo de Notaristefani

Director

Appears on 1 filing

Ameet Nathwani

Director

Appears on 1 filing

Raj Kannan

Executive Officer, Director

Appears on 1 filing

Jan Van de Bossche

Director

Appears on 1 filing

Claudio Nessi

Director

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Dec 29, 2025	New	$110,724,980	$56,862,480	17

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Telemachus Therapeutics, Inc.

Pharmaceuticals

Offering target: $1,500,000

Filed Oct 28, 2026